Sarepta Therapeutics (SRPT) Asset Writedowns and Impairment (2010 - 2026)

Sarepta Therapeutics' Asset Writedowns and Impairment history runs 6 years deep, the most recent figure standing at $2.6 million for Q4 2022.

• In Q4 2022, Asset Writedowns and Impairment changed N/A year-over-year to $2.6 million; the TTM figure through Dec 2022 stood at $7.1 million (up 64.79% YoY), while the FY2025 annual figure was $165.3 million, changed N/A from the prior year.
• Asset Writedowns and Impairment for Q4 2022 stood at $2.6 million, down from $4.5 million in the prior quarter.
• The five-year high for Asset Writedowns and Impairment was $4.5 million in Q3 2021, with the low at -$202000.0 in Q4 2019.
• The 4-year median for Asset Writedowns and Impairment is $2.6 million (2022), against an average of $2.2 million.
• Peak annual rise in Asset Writedowns and Impairment reached 105.25% in 2019, while the deepest fall reached 105.25% in 2019.
• Sarepta Therapeutics' Asset Writedowns and Impairment stood at $3.8 million in 2018, then plunged by 105.25% to -$202000.0 in 2019, then soared by 2321.78% to $4.5 million in 2021, then plunged by 42.62% to $2.6 million in 2022.
• Business Quant data shows SRPT's Asset Writedowns and Impairment at $2.6 million in Q4 2022, $4.5 million in Q3 2021, and -$202000.0 in Q4 2019.